A detailed history of Charles Schwab Investment Management Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 468,413 shares of ZNTL stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
468,413
Previous 455,937 2.74%
Holding current value
$1.78 Million
Previous $7.19 Million 73.35%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$4.09 - $16.13 $51,026 - $201,237
12,476 Added 2.74%
468,413 $1.92 Million
Q1 2024

May 08, 2024

BUY
$10.83 - $16.49 $109,534 - $166,779
10,114 Added 2.27%
455,937 $7.19 Million
Q4 2023

Feb 06, 2024

BUY
$9.84 - $20.13 $36,988 - $75,668
3,759 Added 0.85%
445,823 $6.75 Million
Q3 2023

Nov 08, 2023

BUY
$19.63 - $28.29 $710,978 - $1.02 Million
36,219 Added 8.92%
442,064 $8.87 Million
Q2 2023

Aug 09, 2023

BUY
$17.41 - $30.05 $1.26 Million - $2.17 Million
72,277 Added 21.67%
405,845 $11.4 Million
Q1 2023

May 11, 2023

SELL
$16.14 - $24.94 $35,330 - $54,593
-2,189 Reduced 0.65%
333,568 $5.74 Million
Q4 2022

Feb 13, 2023

BUY
$18.07 - $25.6 $221,429 - $313,702
12,254 Added 3.79%
335,757 $6.76 Million
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $59,880 - $93,920
2,960 Added 0.92%
323,503 $7.01 Million
Q2 2022

Aug 15, 2022

BUY
$17.91 - $52.25 $943,964 - $2.75 Million
52,706 Added 19.68%
320,543 $9.01 Million
Q1 2022

May 13, 2022

BUY
$41.58 - $80.89 $284,032 - $552,559
6,831 Added 2.62%
267,837 $12.4 Million
Q4 2021

Feb 11, 2022

BUY
$66.92 - $84.79 $565,875 - $716,984
8,456 Added 3.35%
261,006 $21.9 Million
Q3 2021

Nov 16, 2021

BUY
$46.83 - $73.5 $4.6 Million - $7.22 Million
98,286 Added 63.71%
252,550 $16.8 Million
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $950,924 - $1.58 Million
25,419 Added 19.73%
154,264 $8.21 Million
Q1 2021

May 17, 2021

BUY
$35.69 - $52.72 $155,501 - $229,701
4,357 Added 3.5%
128,845 $5.59 Million
Q4 2020

Feb 16, 2021

BUY
$31.71 - $57.97 $1.2 Million - $2.19 Million
37,817 Added 43.63%
124,488 $6.47 Million
Q3 2020

Nov 13, 2020

BUY
$27.03 - $47.97 $564,007 - $1 Million
20,866 Added 31.71%
86,671 $2.83 Million
Q2 2020

Aug 14, 2020

BUY
$23.2 - $54.8 $1.53 Million - $3.61 Million
65,805 New
65,805 $3.16 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $217M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.